Trial
NCT02209376
Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
University of California, San Francisco
Condition
Patients With Residual or Reccurent EGFRvIII+ Glioma
Intervention
CART-EGFRvIII T cells
Why stopped
Sponsor decision to terminate prior to completion to pursue combination therapies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22